- Home
- / MDxHealth
MDxHealth
Stock Price
€3
2023-12-15
Market Capitalization
€85.6 M
2023-12-15
Revenue
$107.9 M
FY, 2025
MDxHealth Summary
Company Summary
- Overview
- MDxHealth is a molecular diagnostics company that develops and commercializes tests for cancer and other urologic diseases diagnosis. It offers SelectMDx and ConfirmMDx, prostate cancer genomic testing solutions based on proprietary genetic, epigenetic, and other complex molecular technologies.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Herstal, BE | view all locations
- Website
- https://mdxhealth.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
John Bellano, Chief Commercial Officer
Ron Kalfus, Chief Financial Officer
Joseph Sollee, Executive Vice President of Corporate Development and General Counsel
Operating MetricsView all
Patients Tested to Date
33K
13.8%
FY, 2021
Billable Test Volume
28.9K
2.8%
FY, 2021
Customers
1K
FY, 2021
LocationsView all
4 locations detected
Herstal, Wallonie HQ
Belgium
Rue d’Abhooz, 31
Irvine, CA
United States
15279 Alton Parkway Suite 100
Plano, TX
United States
7000 Preston Rd #1500
Nijmegen, GE
Netherlands
Transistorweg 5
MDxHealth Financials
Summary Financials
- Revenue (Q1, 2026)
- $27.4M
- Gross profit (Q1, 2026)
- $16.6M
- Net income (Q1, 2026)
- ($8.9M)
- Cash (Q1, 2026)
- $43.2M
- EBIT (Q1, 2026)
- ($7.3M)
- Enterprise value
- $143.2M